Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma
ABBV-368、tilsotolimod、budigalimab 和 nab-paclitaxel 联合治疗复发/转移性头颈部鳞状细胞癌患者的 1b 期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-014086
Daste, Amaury; Le, Xiuning; Makkouk, Amani; Patel, Maulik; Le Tourneau, Christophe; Perets, Ruth; Popovtzer, Aron; Ochsenreither, Sebastian; Haderlein, Marlen; Oliva, Marc; Sukari, Ammar; Hong, Jaehyung; Blaney, Martha; Ramathal, Cyril; McDevitt, Michael; Rosenberg, Ari J